Prediction of the long-term outcomes associated with body mass index and advanced gastric cancer.

2016 ◽  
Vol 34 (4_suppl) ◽  
pp. 82-82
Author(s):  
Jae Gyu Kim ◽  
Beom Jin Kim ◽  
Kyong-Choun Chi ◽  
Jung Min Park ◽  
Mi Kyoung Kim ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Body Mass Index ◽  
Advanced Gastric Cancer ◽  
Body Mass ◽  
Disease Free Survival ◽  
Stage Ii ◽  
Stage Iii ◽  
Long Term Outcomes ◽  
Significant Difference

82 Background: Radical gastrectomy followed by adjuvant chemotherapy for advanced gastric cancer brings about serious nutritional impairment. Recent studies have shown an association between body mass index (BMI) and perioperative outcomes of gastric cancer. However, little is known about the association between BMI and long-term outcomes of advanced gastric cancer. Our study evaluated the clinical impact of BMI on the long-term outcomes of gastric cancer staged at II and III, treated by radical gastrectomy followed by adjuvant chemotherapy. Methods: We analysed a total of 211 cases of advanced gastric cancer stage II and III between January 2005 and December 2010 at Chung-Ang University Hospital. The patients were divided into 4 groups according to BMI; underweight, normal, overweight, and obese. In addition, they were divided into two groups (BMI-High vs BMI-Low). We assessed age, sex, tumor location, lymph node involvement, operation method, initial cancer stage, recurrence, and survival (overall survival and disease free survival) between two groups. Results: We classified them into 4 groups according to BMI; underweight, normal, overweight, and obese. There was no difference in overall survival between normal, overweight, and obese group. However, there was significant difference between underweight group and the other groups. As for disease free survival, similar findings were observed. Among 211 patients, 154 patients (72.9%) were included in BMI-L (body mass index < 25), whereas 57 patients (27.1%) in BMI-H (body mass index ≥ 25). There was no difference in age, sex, tumor location, stage, lymph node involvement, operation method, recurrence, and cancer-related death between two groups. When classified into 4 groups as stage II in BMI-H, stage II in BMI-L, stage III in BMI-H, and stage III in BMI-L, overall survival showed significant difference in stage, however, no difference between BMI-H and BMI-L. Disease free survival showed no significant difference in stage and BMI, especially, no significant difference between stage II in BMI-L and stage III in BMI –H. Conclusions: Our findings suggest that preoperative BMI may predict the long term outcomes of advanced gastric cancer after radical surgery and chemotherapy.

Short- and long-term outcomes following laparoscopic gastrectomy for advanced gastric cancer compared with open gastrectomy.

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 369-369
Author(s):  
Kazuaki Shibuya ◽  
Hideki Kawamura ◽  
Yosuke Ohno ◽  
Nobuki Ichikawa ◽  
Tadashi Yoshida ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Laparoscopic Gastrectomy ◽  
Clinical Stage ◽  
Stage Ii ◽  
Open Gastrectomy ◽  
Long Term Outcomes ◽  
Significant Difference ◽  
Short And Long Term

369 Background: To investigate the oncological feasibility and technical safety of laparoscopic gastrectomy with D2 lymphadenectomy for advanced gastric cancer. Methods: 186 advanced gastric cancer patients treated by gastrectomy with D2 lymphadenectomy were eligible for inclusion including those with invasion into the muscularis propria, subserosa, and serosa without involvement of other organs, and stages N0–2 and M0. We retrospectively compared the short- and-long term outcomes between laparoscopic gastrectomy and open gastrectomy. Results: We analyzed short-term outcomes by comparing distal- with total gastrectomy results. We found no significant difference for distal gastrectomy for postoperative morbidity (laparoscopic vs. open: n = 4 (4.6%) vs. n = 1 (3.6%); p= 1.00). We also found no significant difference in postoperative morbidity for total gastrectomy (laparoscopic vs. open: n = 2 (4.0%) vs. n = 1 (4.0%); p= 1.00). No deaths occurred in any group. The entire cohort analysis revealed no statistically significant differences in overall- or recurrence-free survival between the laparoscopic and open groups. For overall survival, there were no significant differences between open and laparoscopic groups for clinical stage II or III ( p= 0.29 and 0.27, respectively), and for pathological stage II or III ( p= 0.88 and 0.86, respectively). For recurrence-free survival, there were no significant differences between open and laparoscopic groups for clinical stage II or III ( p= 0.63 and 0.60, respectively), and for pathological stage II or III (p = 0.98 and 0.72, respectively). Conclusions: Laparscopic gastrectomy for advanced gastric cancer compared favorably with open gastrectomy regarding short- and long-term outcomes. Clinical trial information: 160907.

Sa1989 Body Mass Index May Predict the Long-Term Outcomes of Advanced Gastric Cancer

2016 ◽  
Vol 150 (4) ◽  
pp. S425
Author(s):  
Jae G. Kim ◽  
Beom Jin Kim ◽  
Kyung Cheon Chi ◽  
Jung Min Park ◽  
Mi Kyoung Kim ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Body Mass Index ◽  
Advanced Gastric Cancer ◽  
Body Mass ◽  
Long Term Outcomes

Long-term results of surgical treatment of gastric cancer

1986 ◽  
Vol 67 (2) ◽  
pp. 104-106
Author(s):  
A. S. Abdullin ◽  
F. Sh. Akhmetzyanov ◽  
A. A. Samigullin ◽  
Z. N. Shemeunova ◽  
V. A. Arinin ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Surgical Treatment ◽  
Stomach Cancer ◽  
Stage Iv ◽  
Stage Ii ◽  
Stage Iii ◽  
Disease Stage ◽  
Long Term Results ◽  
Long Term Outcomes

We analyzed long-term outcomes of the treatment of 217 patients (men - 126, women - 91), who underwent radical operations for stomach cancer in the period of 1972 till 1976. 14 patients were under 39, 52 - from 40 to 49, 50 to 59 - 52, 60 to 69 - 80, over 70 years old - 19. The youngest patient was 28 years old and the oldest - 76 years old. Most patients (185) were operated on at stage III of the disease, stage II was diagnosed in 27 patients, and stage IV - in 5 patients.

scholarly journals Body mass index and long-term outcomes in stage III colon cancer patients administered postoperative chemotherapy

2017 ◽  
Vol 28 ◽  
pp. iii100-iii101
Author(s):  
Jolanta Zok ◽  
Renata Duchnowska ◽  
Barbara Radecka ◽  
Krzysztof Adamowicz ◽  
Jan Korniluk ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Colon Cancer ◽  
Cancer Patients ◽  
Body Mass ◽  
Postoperative Chemotherapy ◽  
Stage Iii ◽  
Long Term Outcomes ◽  
Stage Iii Colon Cancer

scholarly journals A Novel Bedside HIPEC as Adjuvant Therapy for Stage III Gastric Cancer Patients after D2 Radical  Gastrectomy

2021 ◽  
Author(s):  
Lili Liu ◽  
Li Sun ◽  
Ning Zhang ◽  
Cheng-gong Liao ◽  
Haichuan Su ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Therapy ◽  
Oral Administration ◽  
Advanced Gastric Cancer ◽  
Disease Free Survival ◽  
Stage Iii ◽  
Control Treatment ◽  
Control Group ◽  
D2 Gastrectomy ◽  
Significant Difference

Abstract Background To investigate the efficacy and safety of a novel bedside prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced gastric cancer after radical D2 gastrectomy.Methods Total 114 patients with stage III gastric cancer were randomly assigned to bedside HIPEC or control treatment groups two weeks after radical D2 gastrectomy. HIPEC group was treated with cisplatin (60 mg/m2) through HIPEC, which was given on day 1 and 3 (30 mg/m2 each time), plus oral administration of S-1 twice daily at 40–60 mg/time for 14 days. Control group was treated with cisplatin (60 mg/m2), which was administered intravenously once, plus oral administration of S-1 twice daily, 40–60 mg/time, for 14 days. Patients in either group were given 6–8 cycles of the therapy.Results Median of disease-free survival (DFS) was 21.0 months in the HIPEC group, which was significantly longer than that in the control group (14.0 months, P = 0.039). The rate of 2-year DFS in the HIPEC group was higher than that in the control group although it was not statistically significant (47.3% vs 29.4%). In contrast, incidence of peritoneal metastasis was lower in the HIPEC (6/57, 10.5%) in comparison to that in the control group (12/57, 21.1%, P = 0.198). Patients in both groups completed an average of 5.9 cycles of the therapy with no significant difference in the incidence of adverse effects (except thrombocytopenia).Conclusion HIPEC with cisplatin plus oral S-1 is a safe and effective adjuvant therapy for the patients with advanced gastric cancer following radical D2 gastrectomy.

scholarly journals Effect of High Body Mass Index on Short- and Long-term Outcomes of Patients who Underwent Laparoscopic Gastrectomy for Advanced Gastric Cancer: A Case Control Study

2020 ◽  
Author(s):  
Tianqi Luo ◽  
Guoming Chen ◽  
Chengcai Liang ◽  
Kaiming Jiang ◽  
Kai Lei ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Body Mass Index ◽  
Operation Time ◽  
High Body Mass Index ◽  
Long Term Outcomes ◽  
Intraoperative Bleeding ◽  
Significant Difference ◽  
Short And Long Term ◽  
High Bmi

Abstract Background High body mass index (BMI) is thought to be a preoperative risk factor for surgical treatment. Until now, few studies have investigated the long-term impact of preoperative high BMI on advanced gastric cancer (GC) patients who underwent laparoscopic gastrectomy (LG). Therefore, the present study was designed to compare clinical outcomes between high BMI and normal BMI patients who underwent LG. MethodsWe retrospectively investigated 282 pathological stage II~III GC cases who underwent radical LG plus D2 lymphadenectomy from February 2009 to May 2018. Based on the China BMI classification, the patients were classified into a high (BMI ≥ 24 kg/m2) or normal (BMI < 24 kg/m2) BMI group. The clinical characteristics, intraoperative findings, short-term and long-term outcomes of the two groups of patients were then compared. Results The high BMI group had longer operation time (160.1 ± 36.0 minutes vs. 147.7 ± 33.7 minutes; P = 0.005) and greater intraoperative bleeding (138.3 ± 239.4ml vs. 86.6 ± 67.7ml; P = 0.002) compared to the normal BMI group. Moreover, shorter time to flatus, starting the soft diet, removing drain tube and length of stay (all P < 0.05) were observed in the high BMI patients. However, there was no significant difference in relapse-free survival or overall survival between the two groups. Conclusion Patients with high BMI was associated with longer operation time and greater amount of intraoperative bleeding but had faster recovery as compared to those with normal BMI. Also, LG can be considered as safe with no significant difference in terms of short- and long-term outcomes on the peri- and post-operative outcomes between the two BMI groups of patients. Nevertheless, these surgeries for high BMI patients should be performed by experienced surgeons.

scholarly journals The Prognostic Role of Body Mass Index in Survival of Non-metastatic Postoperative Patients with Colorectal Cancer

2021 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Azar Fanipakdel ◽  
Sareh Hosseini ◽  
Seyed Alireza Javadinia ◽  
Farzin Afkhami Jeddi ◽  
Mostafa Vasei
Keyword(s):  
Colorectal Cancer ◽  
Body Mass Index ◽  
Body Mass ◽  
Disease Free Survival ◽  
Normal Weight ◽  
Prognostic Role ◽  
Significance Level ◽  
Cox Proportional Hazard ◽  
Significant Difference

Background: Rather body mass index (BMI) has a potential prognostic role in determining the outcome of patients suffering from colorectal cancer or not should be clear. Objectives: We aimed at determining the potential effects of BMI on the prognosis of patients with colorectal cancer. Methods: In this cohort study, documents of 1550 patients with colorectal cancer between 2002 and 2020 from Omid hospital and Emam Reza hospital (Mashhad, Iran) databases were evaluated, retrospectively. The multivariable logistic regression and Cox proportional hazard regressions were used at the significance level of P < 0.05. Results: Nine hundred twenty patients included in the current study. Most of patients were categorized as normal weight (38.91%). The prevalence of underweight and overweight/obese were 26.19% and 34.9%, respectively. There was no significant difference in the overall survival (OS) and disease-free survival (DFS) based on BMI (OS: 108.2 ± 7.0 months for underweight, 124.0 ± 6.2 months for normal weight, and 130.9 ± 4.5 months for overweight/obese patients; P = 0.2 and DFS: 97.0 ± 6.5, 110.0 ± 5.6, and 113.7 ± 5.0, respectively; P = 0.3). Conclusions: The BMI had no significant effect on long-term outcomes of patients with colorectal cancer. However, there was an insignificant trend to better outcome in patients with higher BMI comparing the underweight group.

scholarly journals Impact of the Number of Dissected Lymph Nodes on Survival for Gastric Cancer after Distal Subtotal Gastrectomy

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Chang-Ming Huang ◽  
Jian-Xian Lin ◽  
Chao-Hui Zheng ◽  
Ping Li ◽  
Jian-Wei Xie ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Survival Rate ◽  
Lymph Nodes ◽  
Distal Gastrectomy ◽  
Stage I ◽  
Stage Ii ◽  
Stage Iii ◽  
Prognostic Impact ◽  
Term Survival

Objectives. To investigate the prognostic impact of the number of dissected lymph nodes (LNs) in gastric cancer after curative distal gastrectomy.Methods. The survival of 634 patients who underwent curative distal gastrectomy from 1995 to 2004 was retrieved. Long-term surgical outcomes and associations between the number of dissected LNs and the 5-year survival rate were investigated.Results. The number of dissected LNs was one of the most important prognostic indicators. Among patients with comparable T category, the larger the number of dissected LNs was, the better the survival would be (). The linear regression showed that a significant survival improvement based on increasing retrieved LNs for stage II, III and IV (). A cut-point analysis yields the greatest variance of survival rate difference at the levels of 15 LNs (stage I), 25 LNs (stage II) and 30 LNs (stage III).Conclusion. The number of dissected LNs is an independent prognostic factor for gastric cancer. To improve the long-term survival of patients with gastric cancer, removing at least 15 LNs for stage I, 25 LNs for stage II, and 30 LNs for stage III patients during curative distal gastrectomy is recommended.

Clinical Staging for Sleep-Disordered Breathing

2002 ◽  
Vol 127 (1) ◽  
pp. 13-21 ◽  
Author(s):  
Michael Friedman ◽  
Hani Ibrahim ◽  
Lee Bass
Keyword(s):  
Body Mass Index ◽  
Success Rate ◽  
Body Mass ◽  
Sleep Disordered Breathing ◽  
Staging System ◽  
Stage I ◽  
Stage Ii ◽  
Stage Iii ◽  
Clinical Staging ◽  
Disordered Breathing

OBJECTIVE: The purpose of this study was to identify prognostic indicators that would lead to stratification of patients likely to have successful surgery for sleep-disordered breathing (SDB) versus those destined to fail. STUDY DESIGN: We retrospectively reviewed 134 patients to correlate palate position and tonsil size to the success of the UPPP as based on postoperative polysomnography results. Similar to our previously published data on the Friedman Score as a predictor of the presence and severity of SDB, the palate position was determined on physical examination of the oral cavity and was graded for each patient. This grade combined with tonsil size was used to stage the patients. Stage I was defined as having palate position 1 or 2 combined with tonsil size 3 or 4. Stage II was defined as having palate position 3 or 4 and tonsil size 3 or 4. Stage III patients had palate position 3 or 4 and tonsil size 0, 1, or 2. Any patient with body mass index of greater than 40 was placed in the stage III group. The results of uvulopalatopharyngoplasty (UPPP) were then graded as success or failure and success rates were compared by stage. SETTING: Academically affiliated tertiary care referral center. RESULTS: Stage I patients who underwent UPPP had a success rate of 80.6%, stage II patients had a success rate of 37.9%, and stage III patients had a success rate of 8.1%. CONCLUSION: A clinical staging system for SDB based on palate position, tonsil size, and body mass index is presented. It appears to be a valuable predictor of the success of UPPP. Additional studies and wider use of the staging system will ultimately define its role in the treatment of SDB.

Sign in / Sign up

Export Citation Format

Share Document